Oculis Holding ( (OCS) ) has issued an announcement.
On February 13, 2025, Oculis Holding AG announced the pricing of an underwritten offering of 5,000,000 ordinary shares at $20.00 per share, aiming to raise $100 million in gross proceeds. The offering, expected to close around February 18, 2025, was oversubscribed and will fund the advancement of Oculis’ clinical development pipeline, particularly the neuroprotective candidate Privosegtor (OCS-05). This move is anticipated to bolster the company’s operational capabilities and enhance its position in the biopharmaceutical industry.
More about Oculis Holding
Oculis is a global biopharmaceutical company that focuses on developing innovative solutions for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. The company’s pipeline includes products such as OCS-01 for diabetic macular edema, Privosegtor (OCS-05) for acute optic neuritis, and Licaminlimab (OCS-02) for dry eye disease. Headquartered in Switzerland, Oculis operates in the U.S. and Iceland and is supported by experienced management and international investors.
YTD Price Performance: 27.58%
Average Trading Volume: 71,173
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $928.8M
For an in-depth examination of OCS stock, go to TipRanks’ Stock Analysis page.